Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. PRAX
  6. >
  7. Valuation
stocks logo

PRAX Valuation

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)

PRAX Relative Valuation

PRAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRAX is overvalued; if below, it's undervalued.

Historical Valuation

Praxis Precision Medicines Inc (PRAX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1577.94 is considered Overvalued compared with the five-year average of -4.80. The fair price of Praxis Precision Medicines Inc (PRAX) is between 23.43 to 40.28 according to relative valuation methord. Compared to the current price of 53.63 USD , Praxis Precision Medicines Inc is Overvalued By 33.13%.
Relative Value
Fair Zone
23.43-40.28
Current Price:53.63
33.13%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.40
P/B
Median3y
2.23
Median5y
2.41
-15.01
FCF Yield
Median3y
-85.78
Median5y
-62.00

Competitors Valuation Multiple

The average P/S ratio for PRAX's competitors is 478.94, providing a benchmark for relative valuation. Praxis Precision Medicines Inc Corp (PRAX) exhibits a P/S ratio of 1577.94, which is 229.46% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap

People Also Watch

FAQ

arrow icon

Is Praxis Precision Medicines Inc (PRAX) currently overvalued or undervalued?

Praxis Precision Medicines Inc (PRAX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1577.94 is considered Overvalued compared with the five-year average of -4.80. The fair price of Praxis Precision Medicines Inc (PRAX) is between 23.43 to 40.28 according to relative valuation methord. Compared to the current price of 53.63 USD , Praxis Precision Medicines Inc is Overvalued By 33.13% .
arrow icon

What is Praxis Precision Medicines Inc (PRAX) fair value?

PRAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Praxis Precision Medicines Inc (PRAX) is between 23.43 to 40.28 according to relative valuation methord.
arrow icon

How does PRAX's valuation metrics compare to the industry average?

The average P/S ratio for PRAX's competitors is 478.94, providing a benchmark for relative valuation. Praxis Precision Medicines Inc Corp (PRAX) exhibits a P/S ratio of 1577.94, which is 229.46% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
arrow icon

What is the current P/B ratio for Praxis Precision Medicines Inc (PRAX) as of Jul 17 2025?

As of Jul 17 2025, Praxis Precision Medicines Inc (PRAX) has a P/B ratio of 2.40. This indicates that the market values PRAX at 2.40 times its book value.
arrow icon

What is the current FCF Yield for Praxis Precision Medicines Inc (PRAX) as of Jul 17 2025?

As of Jul 17 2025, Praxis Precision Medicines Inc (PRAX) has a FCF Yield of -15.01%. This means that for every dollar of Praxis Precision Medicines Inc’s market capitalization, the company generates -15.01 cents in free cash flow.
arrow icon

What is the current Forward P/E ratio for Praxis Precision Medicines Inc (PRAX) as of Jul 17 2025?

As of Jul 17 2025, Praxis Precision Medicines Inc (PRAX) has a Forward P/E ratio of -4.06. This means the market is willing to pay $-4.06 for every dollar of Praxis Precision Medicines Inc’s expected earnings over the next 12 months.
arrow icon

What is the current Forward P/S ratio for Praxis Precision Medicines Inc (PRAX) as of Jul 17 2025?

As of Jul 17 2025, Praxis Precision Medicines Inc (PRAX) has a Forward P/S ratio of 1577.94. This means the market is valuing PRAX at $1577.94 for every dollar of expected revenue over the next 12 months.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free